ProPhase Labs Added to the Russell Microcap Index
June 28 2021 - 8:30AM
ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase” or the “Company”), a
diversified medical science and technology company, today announces
that it has been added to the Russell Microcap Index. This
milestone became effective at the conclusion of the 2021 Russell
Indexes’ annual reconstitution, which occurred immediately
following the U.S. market opening today, June 28, 2021.
“ProPhase’s inclusion in the Russell Microcap
Index marks an important milestone for our Company and presents an
important opportunity for us to further expand awareness of our
company among a broader group of investors, which we expect will
also further enhance our liquidity,” said Ted Karkus, CEO of
ProPhase Labs.
Membership in the Russell Microcap Index, which
remains in place for one year, means automatic inclusion in the
appropriate growth and value style indexes. FTSE Russell determines
membership for its Russell Indexes primarily by objective,
market-capitalization rankings and style attributes.
Russell Indexes are widely used by investment
managers and institutional investors for index funds and as
benchmarks for active investment strategies. Approximately $10.6
trillion in assets are benchmarked against Russell’s U.S. Indexes.
Russell Indexes are part of FTSE Russell, a leading global index
provider.
About ProPhase
Labs
ProPhase Labs, Inc. (Nasdaq: PRPH) is a
diversified medical science and technology company. The Company’s
subsidiary, ProPhase Diagnostics, offers a broad array of clinical
diagnostic insights and testing services at its CLIA certified
laboratories. ProPhase Diagnostics serves patients with SARS-CoV-2
(COVID-19) through both saliva and nasal swab methods. Our
methodology also has the capability to identify the possibility of
mutations. Critical to COVID testing, results are provided in under
24 hours. ProPhase also offers PCR (polymerase chain reaction)
testing for Influenzas A and B and RSV. ProPhase Diagnostics now
offers antigen and antibody/immunity tests in partnership with
scientists to broaden its COVID-19 testing beyond RT-PCR testing.
ProPhase Labs researches, develops, manufactures, distributes,
markets, and sells OTC consumer healthcare products and dietary
supplements, including dietary supplements under the TK
Supplements® brand. ProPhase actively pursues strategic
investments and acquisition opportunities for other companies,
technologies, and products. For more information,
visit www.ProPhaseLabs.com.
Forward Looking Statements
Except for the historical information contained
herein, this document contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements regarding our ability to expand
awareness of our company and enhance our liquidity as a result of
our addition to the Russell Microcap Index. Management believes
that these forward-looking statements are reasonable as and when
made. However, such forward-looking statements involve known and
unknown risks, uncertainties, and other factors that may cause
actual results to differ materially from those projected in the
forward-looking statements. These risks and uncertainties include
but are not limited to the risk factors listed from time to time in
our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and
any other SEC filings.
Investor Contact:Ted Karkus,
Chairman and CEOProPhase Labs, Inc.(267) 880-1111
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
ProPhase Labs (NASDAQ:PRPH)
Historical Stock Chart
From Sep 2023 to Sep 2024